MeSH term
Frequency | Condition_Probility | Female | 51 | 0.0 |
Humans | 106 | 0.0 |
Pregnancy | 9 | 0.0 |
Adolescent | 7 | 0.0 |
Adult | 38 | 0.0 |
Aged | 27 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Gene Frequency | 17 | 0.0 |
Male | 39 | 0.0 |
Middle Aged | 37 | 0.0 |
Nitric-Oxide Synthase/*genetics | 41 | 41.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Research Support, Non-U.S. Gov't | 63 | 0.0 |
Alleles | 24 | 0.0 |
Base Sequence | 7 | 0.0 |
Comparative Study | 8 | 0.0 |
Genotype | 34 | 0.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Nitric Oxide/*metabolism | 6 | 4.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Polymerase Chain Reaction | 15 | 0.0 |
Polymorphism, Genetic/*genetics | 12 | 0.0 |
Pre-Eclampsia/*genetics | 2 | 10.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Animals | 23 | 0.0 |
Endothelin-1/*biosynthesis | 2 | 40.0 |
Immunohistochemistry | 8 | 0.0 |
Alzheimer Disease/epidemiology/*genetics | 2 | 3.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Nitric-Oxide Synthase/analysis/*genetics | 2 | 100.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Body Mass Index | 4 | 0.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Heterozygote | 4 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Lod Score | 2 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Nitric-Oxide Synthase/*biosynthesis | 4 | 14.0 |
English Abstract | 9 | 0.0 |
Nitric-Oxide Synthase/biosynthesis/metabolism | 2 | 66.0 |
Abortion, Habitual/*genetics/physiopathology | 2 | 100.0 |
Mutation, Missense | 2 | 0.0 |
Nitric-Oxide Synthase/*genetics/metabolism | 3 | 15.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Hypertension/*genetics | 3 | 2.0 |
Multivariate Analysis | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Risk Factors | 7 | 0.0 |
Polymorphism, Genetic | 14 | 0.0 |
Case-Control Studies | 9 | 0.0 |
Nitric-Oxide Synthase/*metabolism | 6 | 7.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Russia | 2 | 2.0 |
Isoenzymes/biosynthesis | 2 | 4.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Introns/genetics | 3 | 0.0 |
Risk Assessment | 2 | 0.0 |
Genetic Predisposition to Disease | 12 | 0.0 |
Homozygote | 4 | 0.0 |
*Polymorphism, Genetic | 12 | 0.0 |
Prospective Studies | 3 | 0.0 |
Tandem Repeat Sequences | 2 | 1.0 |
Alzheimer Disease/*genetics | 4 | 1.0 |
Gene Deletion | 3 | 0.0 |
Exons/genetics | 2 | 0.0 |
Reference Values | 3 | 0.0 |
Chi-Square Distribution | 5 | 0.0 |
Lewy Body Disease/*genetics | 2 | 66.0 |
Neoplasm Staging | 4 | 0.0 |
Mutation | 3 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Nitric Oxide/*physiology | 6 | 8.0 |
Nitric-Oxide Synthase/metabolism | 4 | 3.0 |
Endothelium, Vascular/enzymology | 3 | 6.0 |
Aspartic Acid/genetics | 2 | 3.0 |
Child | 2 | 0.0 |
Glutamic Acid/genetics | 2 | 5.0 |
Japan | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Cohort Studies | 3 | 0.0 |
Minisatellite Repeats | 2 | 1.0 |
*Point Mutation | 3 | 0.0 |
Codon/genetics | 2 | 0.0 |
Cells, Cultured | 6 | 0.0 |
DNA Primers | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Asthma/*enzymology/*genetics/immunology | 2 | 66.0 |
Chromosome Mapping | 5 | 0.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Introns | 3 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Nitric-Oxide Synthase/genetics/*metabolism | 4 | 23.0 |
Statistics, Nonparametric | 2 | 0.0 |
Time Factors | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Diabetic Retinopathy/*genetics | 2 | 20.0 |
Disease-Free Survival | 2 | 0.0 |
Exons | 3 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Odds Ratio | 4 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Histocytochemistry | 2 | 0.0 |
Mice | 6 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Adrenergic beta-Agonists/pharmacology | 2 | 4.0 |
Isoproterenol/pharmacology | 2 | 1.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Nitric-Oxide Synthase/genetics/*physiology | 2 | 100.0 |
Phenotype | 5 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Nitric Oxide/biosynthesis | 2 | 2.0 |
Nitric-Oxide Synthase/genetics | 3 | 8.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Rats | 4 | 0.0 |
Endothelium, Vascular/*enzymology | 2 | 4.0 |
Fibrosis | 2 | 1.0 |
Mice, Transgenic | 2 | 0.0 |
Nitric-Oxide Synthase | 5 | 14.0 |
Ventricular Function, Left/physiology | 2 | 11.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Signal Transduction | 3 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Amino Acid Oxidoreductases/*genetics | 3 | 18.0 |
*Genes, Structural | 2 | 0.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Nitric-Oxide Synthase/*genetics/physiology | 2 | 66.0 |
Polymorphism, Genetic/*physiology | 2 | 2.0 |
Exercise/physiology | 2 | 3.0 |
